Test Catalog

Test Id : AMLFA

Adult Acute Myeloid Leukemia Panel, FISH, Varies

Useful For
Suggests clinical disorders or settings where the test may be helpful

Detecting, at diagnosis, recurrent common chromosome abnormalities associated with acute myeloid leukemia (AML) in patients aged 31 and older using a laboratory-designated probe set algorithm

 

As an adjunct to conventional chromosome studies in patients with AML

 

Evaluating specimens in which chromosome studies are unsuccessful

 

This test should not be used to screen for residual AML

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

This test includes a charge for the probe application, analysis, and professional interpretation of results for 3 probe sets (6 individual fluorescence in situ hybridization [FISH] probes). Additional charges will be incurred for all reflex testing or additional probe sets performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.

 

This test is performed as panel testing only using the following analysis algorithm.

 

The initial diagnostic adult acute myeloid leukemia (AML) FISH panel includes testing for the following abnormalities using the FISH probes listed:

t(8;21)(q21.3;q22) or RUNX1::RUNX1T1 fusion, RUNX1T1/RUNX1 probe set

t(11q23;var) or KMT2A rearrangement, KMT2A break-apart probe set

t(15;17)(q24;q21) or PML::RARA fusion, PML/RARA probe set

inv(16) or t(16;16) or CBFB::MYH11 fusion, MYH11/CBFB probe set

 

If testing is ordered concurrently with a chromosomal study (CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow; or CHRHB / Chromosome Analysis, Hematologic Disorders, Blood), secondary testing will not be performed. Appropriate secondary FISH probes will be recommended if the chromosome results are informative.

 

If a chromosome study is not ordered concurrently, the following secondary panel of FISH probes will be performed when the initial panel is negative or demonstrate nonclassical abnormalities:

inv(3) or t(3;3) or GATA2::MECOM fusion, GATA2/MECOM probe set

-5/5q-, D5S630/EGR1 probe set

t(6;9)(p22.3;q34) or DEK::NUP214 fusion, DEK/NUP214 probe set

-7/7q-, D7Z1/D7S486 probe set

t(9;22)(q34;q11.2) or BCR::ABL1 fusion, ABL1/BCR probe set

t(11p15.4;var) or NUP98 rearrangement, NUP98 break-apart probe set

-17/17p-, TP53/D17Z1 probe set

 

Appropriate ancillary probes may be performed at consultant discretion to render comprehensive assessment. Any additional probes will have the results included within the final report and will be performed at an additional charge.

 

In the following situations, additional (reflex) testing may be performed at the laboratory's discretion and may be influenced by available karyotype results or other FISH testing.

 

When a KMT2A rearrangement is identified, 1 or more dual-fusion FISH (D-FISH) probe sets may be used in an attempt to identify the translocation partner for the following abnormalities:

t(4;11)(q21;q23) or KMT2A::AFF1 fusion, AFF1/KMT2A probe set

t(6;11)(q27;q23) or KMT2A::AFDN ;fusion, AFDN/KMT2A probe set

t(9;11)(p22;q23) or KMT2A::MLLT3 fusion, MLLT3/KMT2A probe set

t(10;11)(p12;q23) or KMT2A::MLLT10 fusion, MLLT10/KMT2A probe set

t(11;16)(q23;p13.3) or KMT2A::CREBBP fusion, KMT2A/CREBBP probe set

t(11;19)(q23;p13.1) or KMT2A::MLLT1 fusion, KMT2A/ELL probe set

t(11;19)(q23;p13.3) or KMT2A::ELL fusion, KMT2A/MLLT1 probe set

 

When an extra or atypical RARA signal is identified in the absence of PML::RARA fusion, the RARA break-apart probe set may be used to identify a potential variant translocation involving RARA, t(17;var)(q21;?).

When an extra CBFB signal is identified in the absence of CBFB::MYH11 fusion, the CBFB break-apart probe set may be used to evaluate for the presence or absence of a potential variant translocation involving CBFB, t(16;var)(q22;?).

 

When an extra RUNX1 signal is identified in the absence of RUNX1::RUNX1T1 fusion, the RUNX1 break-apart probe set may be used to evaluate for the presence or absence of a potential variant translocation involving RUNX1, t(21;var)(q22;?).

 

When an extra GATA2 signal is identified in the absence of GATA2::MECOM fusion, the PRDM16/GATA2 probe set may be used to identify a potential t(1;3)(p36;q21).

 

When an extra MECOM signal is identified in the absence of GATA2::MECOM fusion, the break-apart MECOM probe set may be used to identify a potential variant translocation involving MECOM, t(3;var)(q26.2;?).

  

When an extra ABL1 signal is identified in the absence of BCR::ABL1 fusion, the ABL1 break-apart probe set may be used to evaluate for the presence or absence of a potential variant translocation involving ABL1, t(9;var)(q34;?).

 

For more information see:

Acute Promyelocytic Leukemia: Guideline to Diagnosis and Follow-up

Acute Leukemias of Ambiguous Lineage Testing Algorithm

Acute Myeloid Leukemia: Testing Algorithm

Method Name
A short description of the method used to perform the test

Fluorescence In Situ Hybridization (FISH)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Adult-AML panel, FISH

Aliases
Lists additional common names for a test, as an aid in searching

Acute Promyelocytic Leukemia (APL)

AML-M0

AML-M1

AML-M2

AML-M3

AML-M4

AML-M4eo

AML-M5

AML-M7

inv(3)(q21q26)-GATA2::MECOM, GATA2/MECOM, RPN1/MECOM or RPN1/EVI1

t(3;3)(q21;q26)-GATA2::MECOM, GATA2/MECOM, RPN1/MECOM or RPN1/EVI1

t(1;3)(p36;q21)-GATA2::PRDM16, PRDM16/GATA2 or PRDM16/RPN1

MECOM (3q26.2) rearrangement

-5 (monosomy 5)

5q- (5q deletion)

t(6;9)(p22;q34)-DEK::NUP214, DEK/NUP214 or DEK/CAN

-7 (monosomy 7)

7q- (7q deletion)

t(8;21)(q21;q22)-RUNX1::RUNX1T1, RUNX1T1/RUNX1 or ETO/AML1

RUNX1 (21q22) rearrangement

t(9;22)(q34;q11)-BCR::ABL1 or BCR/ABL1

ABL1 (9q34) rearrangement

NUP98 (11p15) rearrangement

MLL or KMT2A (11q23) rearrangement

t(4;11)(q21;q23)-KMT2A::AFF1, AFF1/KMT2A or AFF1/MLL or AF4/MLL

t(6;11)(q27;q23)-KMT2A::AFDN, AFDN/KMT2A or MLLT4/MLL or AF6/MLL

t(9;11)(p21;q23)-KMT2A::MLLT3, MLLT3/KMT2A or MLLT3/MLL or AF9/MLL

t(10;11)(p12;q23)-KMT2A::MLLT10, MLLT10/KMT2A or MLLT10/MLL or AF10/MLL

t(11;16)(q23;p13.3)-KMT2A::CREBBP, KMT2A/CREBBP or MLL/CREBBP

t(11;19)(q23;p13.3)-KMT2A::MLLT1, KMT2A/MLLT1 or MLL/MLLT1 or MLL/ENL

t(11;19)(q23;p13.1)-KMT2A::ELL, KMT2A/ELL or MLL/ELL

t(15;17)(q24;q21)-PML::RARA or PML/RARA

RARA (17q21) rearrangement

inv(16)(p13q22)-CBFB::MYH11 or MYH11/CBFB

t(16;16)(p13;q22)-CBFB::MYH11 or MYH11/CBFB

CBFB (16q22) rearrangement

17p- (17p deletion) or TP53

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

This test includes a charge for the probe application, analysis, and professional interpretation of results for 3 probe sets (6 individual fluorescence in situ hybridization [FISH] probes). Additional charges will be incurred for all reflex testing or additional probe sets performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.

 

This test is performed as panel testing only using the following analysis algorithm.

 

The initial diagnostic adult acute myeloid leukemia (AML) FISH panel includes testing for the following abnormalities using the FISH probes listed:

t(8;21)(q21.3;q22) or RUNX1::RUNX1T1 fusion, RUNX1T1/RUNX1 probe set

t(11q23;var) or KMT2A rearrangement, KMT2A break-apart probe set

t(15;17)(q24;q21) or PML::RARA fusion, PML/RARA probe set

inv(16) or t(16;16) or CBFB::MYH11 fusion, MYH11/CBFB probe set

 

If testing is ordered concurrently with a chromosomal study (CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow; or CHRHB / Chromosome Analysis, Hematologic Disorders, Blood), secondary testing will not be performed. Appropriate secondary FISH probes will be recommended if the chromosome results are informative.

 

If a chromosome study is not ordered concurrently, the following secondary panel of FISH probes will be performed when the initial panel is negative or demonstrate nonclassical abnormalities:

inv(3) or t(3;3) or GATA2::MECOM fusion, GATA2/MECOM probe set

-5/5q-, D5S630/EGR1 probe set

t(6;9)(p22.3;q34) or DEK::NUP214 fusion, DEK/NUP214 probe set

-7/7q-, D7Z1/D7S486 probe set

t(9;22)(q34;q11.2) or BCR::ABL1 fusion, ABL1/BCR probe set

t(11p15.4;var) or NUP98 rearrangement, NUP98 break-apart probe set

-17/17p-, TP53/D17Z1 probe set

 

Appropriate ancillary probes may be performed at consultant discretion to render comprehensive assessment. Any additional probes will have the results included within the final report and will be performed at an additional charge.

 

In the following situations, additional (reflex) testing may be performed at the laboratory's discretion and may be influenced by available karyotype results or other FISH testing.

 

When a KMT2A rearrangement is identified, 1 or more dual-fusion FISH (D-FISH) probe sets may be used in an attempt to identify the translocation partner for the following abnormalities:

t(4;11)(q21;q23) or KMT2A::AFF1 fusion, AFF1/KMT2A probe set

t(6;11)(q27;q23) or KMT2A::AFDN ;fusion, AFDN/KMT2A probe set

t(9;11)(p22;q23) or KMT2A::MLLT3 fusion, MLLT3/KMT2A probe set

t(10;11)(p12;q23) or KMT2A::MLLT10 fusion, MLLT10/KMT2A probe set

t(11;16)(q23;p13.3) or KMT2A::CREBBP fusion, KMT2A/CREBBP probe set

t(11;19)(q23;p13.1) or KMT2A::MLLT1 fusion, KMT2A/ELL probe set

t(11;19)(q23;p13.3) or KMT2A::ELL fusion, KMT2A/MLLT1 probe set

 

When an extra or atypical RARA signal is identified in the absence of PML::RARA fusion, the RARA break-apart probe set may be used to identify a potential variant translocation involving RARA, t(17;var)(q21;?).

When an extra CBFB signal is identified in the absence of CBFB::MYH11 fusion, the CBFB break-apart probe set may be used to evaluate for the presence or absence of a potential variant translocation involving CBFB, t(16;var)(q22;?).

 

When an extra RUNX1 signal is identified in the absence of RUNX1::RUNX1T1 fusion, the RUNX1 break-apart probe set may be used to evaluate for the presence or absence of a potential variant translocation involving RUNX1, t(21;var)(q22;?).

 

When an extra GATA2 signal is identified in the absence of GATA2::MECOM fusion, the PRDM16/GATA2 probe set may be used to identify a potential t(1;3)(p36;q21).

 

When an extra MECOM signal is identified in the absence of GATA2::MECOM fusion, the break-apart MECOM probe set may be used to identify a potential variant translocation involving MECOM, t(3;var)(q26.2;?).

  

When an extra ABL1 signal is identified in the absence of BCR::ABL1 fusion, the ABL1 break-apart probe set may be used to evaluate for the presence or absence of a potential variant translocation involving ABL1, t(9;var)(q34;?).

 

For more information see:

Acute Promyelocytic Leukemia: Guideline to Diagnosis and Follow-up

Acute Leukemias of Ambiguous Lineage Testing Algorithm

Acute Myeloid Leukemia: Testing Algorithm

Specimen Type
Describes the specimen type validated for testing

Varies

Ordering Guidance

This test is only performed on specimens from patients with acute myeloid leukemia (AML) who are age 31 years or older.

 

If acute promyelocytic leukemia is probable and expedited PML/RARA results are needed, order AMLMF / Acute Myeloid Leukemia (AML), Specified FISH, Varies. If PML::RARA fusion is identified in AMLFA, the laboratory will automatically expedite analysis. Results will not be provided until the complete panel testing is finalized. The laboratory is unable to provide preliminary results.

 

This test should NOT be used to screen for residual AML.

 

Minimal residual disease (MRD) monitoring in patients with AML known to have either t(15;17) with PML::RARA fusion, inv(16) or t(16;16) with CBFB::MYH11 fusion, t(8;21) with RUNX1::RUNX1T1 fusion, or t(9;22) with BCR::ABL1 fusion should be performed by quantitative reverse transcriptase polymerase chain reaction and not by fluorescence in situ hybridization (FISH) testing.

 

It is recommended that MRD monitoring in AML patients be performed by AML-MRD flow cytometry rather than FISH testing using individual FISH probe sets. This is particularly true for the deletion/monosomy probe sets (5, 7, 17) which have cutoffs that exceed 10% of nuclei.

 

If targeted AML FISH probes are preferred, order AMLMF / Acute Myeloid Leukemia (AML), Specified FISH, Varies and request specific probes for targeted abnormalities.

 

This test is intended for instances when the entire AML FISH panel is needed for an adult patient.

 

If this test is ordered on a patient aged 30 years or younger, this test will be canceled and automatically reordered by the laboratory as AMLFP / Pediatric Acute Myeloid Leukemia Panel, FISH, Varies.

 

If this test is ordered and the laboratory is informed that the patient is age 30 years or younger and is on a Children's Oncology Group protocol, this test will be canceled and automatically reordered by the laboratory as COGMF / Acute Myeloid Leukemia (AML), Children's Oncology Group Enrollment Testing, FISH, Varies.

 

If either (or both) BALAF / B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), FISH, Adult, Varies; or TALAF / T-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), FISH, Adult, Varies, is ordered concurrently with this test, the laboratory may cancel this test and automatically reorder as AMLMF / Acute Myeloid Leukemia (AML), Specified FISH, Varies with the following FISH probes: RUNX1T1/RUNX1, PML/RARA, MYH11/CBFB, GATA2/MECOM, DEK/NUP214, D5S630/EGFR1, D7Z1/D7S486, TP53/D17Z1, and NUP98 3'/5'. If an abnormality is identified that would result in reflex testing in this test, the same reflex testing will be performed in the AMLMF. This cancellation is necessary to avoid duplicate testing. The break-apart KMT2A probe set will still be performed as part of either the adult B-cell acute lymphoblastic leukemia (B-ALL) or T-ALL FISH panel.

 

For testing paraffin-embedded tissue samples from patients with AML/myeloid sarcoma, order MSTF / Myeloid Sarcoma, FISH, Tissue. If a paraffin-embedded tissue sample is submitted for this test, this test will be canceled and MSTF will be added and performed as the appropriate test.

Additional Testing Requirements

At diagnosis, conventional cytogenetic studies (CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow) and this fluorescence in situ hybridization panel should be performed. If there is limited specimen available, only this test will be performed.

Shipping Instructions

Advise Express Mail or equivalent if not on courier service.

Necessary Information

1. A reason for testing must be provided. If this information is not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.

2. A flow cytometry and/or a bone marrow pathology report should be submitted with each specimen. The laboratory will not reject testing if this information is not provided but appropriate testing and interpretation may be compromised or delayed.

ORDER QUESTIONS AND ANSWERS

Question ID Description Answers
GC147 Reason for Referral
GC148 Specimen Whole blood ACD
Bone marrow ACD
Whole blood Na Hep
Bone marrow Na Hep
Whole blood EDTA
Bone marrow EDTA

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Submit only 1 of the following specimens:

 

Preferred

Specimen Type: Bone marrow

Container/Tube:

Preferred: Yellow top (ACD)

Acceptable: Green top (sodium heparin) or lavender top (EDTA)

Specimen Volume: 2 to 3 mL

Collection Instructions:

1. It is preferable to send the first aspirate from the bone marrow collection.

2. Invert several times to mix bone marrow.

3. Send bone marrow in original tube. Do not aliquot.

 

Acceptable

Specimen Type: Whole blood

Container/Tube:

Preferred: Yellow top (ACD)

Acceptable: Green top (sodium heparin) or lavender top (EDTA)

Specimen Volume: 6 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood in original tube. Do not aliquot.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.

Bone marrow: 1 mL; Whole blood: 2 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Varies Ambient (preferred)
Refrigerated

Useful For
Suggests clinical disorders or settings where the test may be helpful

Detecting, at diagnosis, recurrent common chromosome abnormalities associated with acute myeloid leukemia (AML) in patients aged 31 and older using a laboratory-designated probe set algorithm

 

As an adjunct to conventional chromosome studies in patients with AML

 

Evaluating specimens in which chromosome studies are unsuccessful

 

This test should not be used to screen for residual AML

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

This test includes a charge for the probe application, analysis, and professional interpretation of results for 3 probe sets (6 individual fluorescence in situ hybridization [FISH] probes). Additional charges will be incurred for all reflex testing or additional probe sets performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.

 

This test is performed as panel testing only using the following analysis algorithm.

 

The initial diagnostic adult acute myeloid leukemia (AML) FISH panel includes testing for the following abnormalities using the FISH probes listed:

t(8;21)(q21.3;q22) or RUNX1::RUNX1T1 fusion, RUNX1T1/RUNX1 probe set

t(11q23;var) or KMT2A rearrangement, KMT2A break-apart probe set

t(15;17)(q24;q21) or PML::RARA fusion, PML/RARA probe set

inv(16) or t(16;16) or CBFB::MYH11 fusion, MYH11/CBFB probe set

 

If testing is ordered concurrently with a chromosomal study (CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow; or CHRHB / Chromosome Analysis, Hematologic Disorders, Blood), secondary testing will not be performed. Appropriate secondary FISH probes will be recommended if the chromosome results are informative.

 

If a chromosome study is not ordered concurrently, the following secondary panel of FISH probes will be performed when the initial panel is negative or demonstrate nonclassical abnormalities:

inv(3) or t(3;3) or GATA2::MECOM fusion, GATA2/MECOM probe set

-5/5q-, D5S630/EGR1 probe set

t(6;9)(p22.3;q34) or DEK::NUP214 fusion, DEK/NUP214 probe set

-7/7q-, D7Z1/D7S486 probe set

t(9;22)(q34;q11.2) or BCR::ABL1 fusion, ABL1/BCR probe set

t(11p15.4;var) or NUP98 rearrangement, NUP98 break-apart probe set

-17/17p-, TP53/D17Z1 probe set

 

Appropriate ancillary probes may be performed at consultant discretion to render comprehensive assessment. Any additional probes will have the results included within the final report and will be performed at an additional charge.

 

In the following situations, additional (reflex) testing may be performed at the laboratory's discretion and may be influenced by available karyotype results or other FISH testing.

 

When a KMT2A rearrangement is identified, 1 or more dual-fusion FISH (D-FISH) probe sets may be used in an attempt to identify the translocation partner for the following abnormalities:

t(4;11)(q21;q23) or KMT2A::AFF1 fusion, AFF1/KMT2A probe set

t(6;11)(q27;q23) or KMT2A::AFDN ;fusion, AFDN/KMT2A probe set

t(9;11)(p22;q23) or KMT2A::MLLT3 fusion, MLLT3/KMT2A probe set

t(10;11)(p12;q23) or KMT2A::MLLT10 fusion, MLLT10/KMT2A probe set

t(11;16)(q23;p13.3) or KMT2A::CREBBP fusion, KMT2A/CREBBP probe set

t(11;19)(q23;p13.1) or KMT2A::MLLT1 fusion, KMT2A/ELL probe set

t(11;19)(q23;p13.3) or KMT2A::ELL fusion, KMT2A/MLLT1 probe set

 

When an extra or atypical RARA signal is identified in the absence of PML::RARA fusion, the RARA break-apart probe set may be used to identify a potential variant translocation involving RARA, t(17;var)(q21;?).

When an extra CBFB signal is identified in the absence of CBFB::MYH11 fusion, the CBFB break-apart probe set may be used to evaluate for the presence or absence of a potential variant translocation involving CBFB, t(16;var)(q22;?).

 

When an extra RUNX1 signal is identified in the absence of RUNX1::RUNX1T1 fusion, the RUNX1 break-apart probe set may be used to evaluate for the presence or absence of a potential variant translocation involving RUNX1, t(21;var)(q22;?).

 

When an extra GATA2 signal is identified in the absence of GATA2::MECOM fusion, the PRDM16/GATA2 probe set may be used to identify a potential t(1;3)(p36;q21).

 

When an extra MECOM signal is identified in the absence of GATA2::MECOM fusion, the break-apart MECOM probe set may be used to identify a potential variant translocation involving MECOM, t(3;var)(q26.2;?).

  

When an extra ABL1 signal is identified in the absence of BCR::ABL1 fusion, the ABL1 break-apart probe set may be used to evaluate for the presence or absence of a potential variant translocation involving ABL1, t(9;var)(q34;?).

 

For more information see:

Acute Promyelocytic Leukemia: Guideline to Diagnosis and Follow-up

Acute Leukemias of Ambiguous Lineage Testing Algorithm

Acute Myeloid Leukemia: Testing Algorithm

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Acute myeloid leukemia (AML) is one of the most common adult leukemias, with almost 10,000 new cases diagnosed per year. AML also comprises 15% of pediatric acute leukemia and accounts for the majority of infant (<1 year old) leukemia.

 

Several recurrent chromosomal abnormalities have been identified in AML with associated clinical significance. The most common chromosome abnormalities associated with AML include t(8;21), t(15;17), inv(16) or t(16;16), and rearrangements of the KMT2A gene at 11q23. The most common genes juxtaposed with KMT2A through translocation events in AML include MLLT3- t(9;11), AFDN- t(6;11), MLLT10- t(10;11), and ELL- t(11;19p13.1).

 

Other recurrent chromosome abnormalities associated with AML include inv(3) or t(3;3), t(6;9), t(9;22), and abnormalities of the NUP98 gene at 11p15.4. In addition, AML can also evolve from myelodysplasia (MDS). Thus, the common chromosome abnormalities associated with MDS can also be identified in AML, which include: -5/5q-, -7/7q-, and 17p-. Overall, the recurrent chromosome abnormalities identified in patients with AML are observed in approximately 60% of diagnostic AML cases.

 

Conventional chromosome analysis is the gold standard for identification of the common, recurrent chromosome abnormalities in AML. However, some of the subtle rearrangements can be missed by karyotype, including inv(16) or t(16;16) and KMT2A rearrangements.

 

Fluorescence in situ hybridization analysis of nonproliferating (interphase) cells can be used to detect the common diagnostic and prognostic chromosome abnormalities observed in patients with AML.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Interpretation
Provides information to assist in interpretation of the test results

A neoplastic clone is detected when the percent of cells with an abnormality exceeds the normal reference range for any given probe set.

 

The absence of an abnormal clone does not rule out the presence of an acute myeloid leukemia clone or another neoplastic disorder.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This test is not approved by the US Food and Drug Administration, and it is best used as an adjunct to clinical and pathologic information.

 

Fluorescence in situ hybridization (FISH) is not a substitute for conventional chromosome studies because the latter detects chromosome abnormalities associated with other hematological disorders that would go undetected in a targeted acute myeloid leukemia FISH panel test.

 

Bone marrow is the preferred specimen type for this FISH test. If bone marrow is not available, a blood specimen may be used if there are circulating myeloblasts in the blood specimen (as verified by a hematopathologist).

 

If no FISH signals are observed post-hybridization, the case will be released indicating a lack of FISH results.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues. 4th ed. IARC Press; 2017

2. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447. doi:10.1182/blood-2016-08-733196

3. Pollyea DA, Bixby D, Perl A, et al. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16-27. Published 2021 Jan 6. doi:10.6004/jnccn.2021.0002

Method Description
Describes how the test is performed and provides a method-specific reference

This test is performed using commercially available and laboratory-developed fluorescence in situ hybridization (FISH) probes. Deletion or monosomy of chromosomes 5, 7, and 17 are detected using enumeration strategy probes. Rearrangements involving MECOM, ABL1, NUP98, KMT2A, CBFB, RARA, and RUNX1 are detected using a dual-color break-apart (BAP) strategy probe. Dual-color, dual-fusion FISH (D-FISH) strategy probe sets are used to detect t(1;3), inv(3) or t(3;3), t(6;9), t(8;21), t(9;22), t(15;17), inv(16) or t(16;16), and in reflex testing when rearrangements of the KMT2A gene are detected. For enumeration and BAP strategy probe sets, 100 interphase nuclei are scored; 200 interphase nuclei are scored when D-FISH probes are used. All results are expressed as the percent abnormal nuclei.(Unpublished Mayo method)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Friday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

7 to 10 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

4 weeks

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Mayo Clinic Laboratories - Rochester Main Campus
CLIA Number: 24D0404292

Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

88271x6, 88275x3, 88291x1-FISH Probe, Analysis, Interpretation; 3 probe sets

88271x2, 88275x1-FISH Probe, Analysis; each additional probe set (if appropriate)

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
AMLFA Adult-AML panel, FISH 102101-3
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
622381 Result Summary 50397-9
622382 Interpretation 69965-2
622383 Result Table 93356-4
622384 Result 62356-1
GC147 Reason for Referral 42349-1
GC148 Specimen 31208-2
622385 Source 31208-2
622386 Method 85069-3
622387 Additional Information 48767-8
622388 Disclaimer 62364-5
622389 Released By 18771-6

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports

Test Update Resources

Change Type Effective Date
New Test 2025-09-09